ArticleCureus2026
From Effect Sizes to Clinical Probabilities: An Exploratory Methodological Framework for Evidence Interpretation and Communication.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEffect sizes such as mean differences (MDs) and standardized mean differences (SMDs) are widely used to summarize treatment effects. However, these measures do not directly indicate the likelihood of clinically meaningful improvement and may be difficult to interpret in clinical practice. This study presents an exploratory methodological framework for re-expressing effect sizes as clinically meaningful probabilities and examines whether these probabilities can support the interpretation and communication of evidence.
methodsWe applied the proposed framework to published effect sizes from representative acupuncture randomized controlled trials and meta-analyses. Assuming normal distributions, MDs and SMDs were re-expressed as probabilities of improvement, worsening, and stability using minimal clinically important difference (MCID) thresholds. These probabilities were further expressed using odds ratios (ORs), therapeutic leverage ratios (TLRs), and absolute probability differences (ΔP). Sensitivity analyses were performed to examine the influence of MCID thresholds, effect sizes, baseline probabilities, and distributional assumptions on probability-based interpretations.
resultsPreviously reported MDs and SMDs could be re-expressed as probabilities of improvement, worsening, and stability. ORs, TLRs, and ΔP provided different perspectives on the same probability changes. Sensitivity analyses showed that absolute probabilities varied across assumptions, whereas the overall three-category structure of improvement, worsening, and stability was preserved across all scenarios.
conclusionRe-expressing effect sizes as clinical probabilities may provide a more intuitive interpretation of population-level evidence. This framework enables the interpretation of improvement, worsening, and stability simultaneously from a single effect size using complementary probability metrics. Although not intended for individual prediction, it may support evidence interpretation when patient-specific information is still limited. In routine clinical practice, however, evidence should ultimately be applied in conjunction with patient-specific information obtained through history taking and clinical examination. Future prospective studies using individual patient data are needed to validate this framework and evaluate its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.